Theravance's $250M in Notes to Pay GSK LABA Milestones
Theravance Inc., of South San Francisco, will use proceeds of a $250 million aggregate principal amount of convertible subordinated notes due 2023 to make milestone payments to GlaxoSmithKline plc upon launch of products developed under the two companies' collaboration around long-acting beta 2 agonists (LABAs).
To continue reading subscribe now to BioWorld Today
Learn More about BioWorld Today
Already a subscriber? Sign In or Buy now to activate your subscription
Note: our contact information has changed
Customer Care: http://support.clarivate.com
© 2018 Clarivate Analytics.
Reproduction, reposting content is strictly prohibited.
Reproduction, reposting content is strictly prohibited.